Relapse and Rehospitalization: Comparing Oral and Depot Antipsychotics

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 16, 2003, Pages 14-17

  Schooler, Nina R ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PIMOZIDE; PLACEBO; TRIFLUOPERAZINE;

CLINICAL TRIAL; CONFERENCE PAPER; DEMOGRAPHY; DISEASE EXACERBATION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; INJECTION; META ANALYSIS; OUTCOMES RESEARCH; OUTPATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SYMPTOM; TECHNIQUE;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; PATIENT READMISSION; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0346753734     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Caffey EM, Diamond LS, Frank TV, et al. Discontinuation or reduction of chemotherapy in chronic schizophrenics. J Chronic Dis 1964;17:347-358
2. Hogarty GE, Goldberg SC, Schooler NR, et al. Drugs and sociotherapy in the aftercare of schizophrenia patients, 2: two-year relapse rates. Arch Gen Psychiatry 1974;31:603-608
3. Prien RF, Cole JO. High-dose chlorpromazine therapy in chronic schizophrenia: report of National Institute of Mental Health-psychopharmacology research branch collaborative study group. Arch Gen Psychiatry 1968;18:482-495
4. Kane JM, Rifkin A, Quitkin F, et al. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982;39:70-73
5. Robinson D, Woerner MG, Alvir J, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
6. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. Arch Gen Psychiatry 1997;54:453-463
7. Davis JM, Kane JM, Marder SR, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993;54(3, suppl):24-30
8. Denham J, Adamson L. The contribution of fluphenazine enanthate and decanoate in the prevention of readmission of schizophrenic patients. Acta Psychiatr Scand 1971;47:420-430
9. Freeman H. Long-acting neuroleptics and their place in community mental health services in the United Kingdom: the Salford experience. Acta Psychiatr Belg 1976;76:786-791
10. Johnson DAW. Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia. Br J Psychiatry 1975;126:457-461
11. Marriott P, Hiep A. A mirror image outpatient study at a depot phenothiazine clinic. Aust N Z J Psychiatry 1976;10:163-167
12. Polonowitz A, James NM. Fluphenazine decanoate maintenance in schizophrenia: a retrospective study. N Z Med J 1976;83:316-318
13. Crawford R, Forrest A. Controlled trial of depot fluphenazine in outpatient schizophrenics. Br J Psychiatry 1974;124:385-391
14. del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 1975;16:32-36
15. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978;8:59-70
16. Hogarty GE, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 1979;36:1283-1294
17. Rifkin A, Quitkin F, Rabiner C, et al. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. Arch Gen Psychiatry 1977;34:43-47
18. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia. Arch Gen Psychiatry 1980;37:16-24
19. Kane JM, Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull 1985;21:23-27
20. Goldberg SC, Schooler NR, Davidson EM, et al. Sex and race differences in response to drug treatment among schizophrenics. Psychopharmacologia (Berl) 1966;9:31-47
21. Adams CE, Fenton MKP, Quiraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001;179:290-299